uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Study Details
Study Description
Brief Summary
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Patients may be enrolled prospectively, at the time of receiving Jelmyto, or after receiving Jelmyto for retrospective data capture and prospective follow up. Patients will be followed until 3 years after the first dose of Jelmyto or death.
Data will be captured to address specific clinical questions and data gaps related to real world use of Jelmyto.
Example clinical questions:
-
How is Jelmyto used in the real world setting?
-
What adverse events (AEs) and at what rates and time points are they observed in the real world setting?
-
What is the disease volume before and after resection/ablation prior to treating with Jelmyto?
-
Did the use of Jelmyto impact clinical decision making and management?
-
What is the complete response (CR) rate, duration of response, and rate of progression, including subgroups of interest?
-
What are the rates of, time to, and pathology at radical nephroureterectomy (RNU) by response to treatment and number of Jelmyto doses received?
-
What are outcomes for non-responders or partial responders? What are the rates of surgical and therapeutic treatment options received following response assessment, including additional Jelmyto?
-
What was the outcome of patients with solitary kidney and/or chronic kidney disease (CKD)? Did Jelmyto prevent dialysis by avoiding nephrectomy in solitary kidney or in patients with baseline CKD?
-
What is the rate and timing of bladder cancer occurrence and/or recurrences?
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Jelmyto Patients with UTUC treated with Jelmyto |
Drug: Jelmyto (mitomycin) for pyelocalyceal solution
The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).
Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- CR rate at first evaluation post-treatment [3 months]
Secondary Outcome Measures
- Duration of response [3 years]
- Rate of progression [3 years]
- Rates and clinical significance of AEs [3 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of UTUC
-
Meet at least one of the following criteria:
-
Have been treated with Jelmyto after April 2020
-
Currently undergoing treatment with Jelmyto
-
Will receive Jelmyto
Exclusion Criteria: None
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- UroGen Pharma Ltd.
Investigators
- Principal Investigator: Yair Lotan, MD, UT Southwestern Medical Center at Dallas
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UT004